Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Harvard Bioscience (HBIO) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $5.5 million.

  • Harvard Bioscience's Other Operating Expenses fell 2019.85% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.5 million, marking a year-over-year increase of 14761.14%. This contributed to the annual value of $29.1 million for FY2024, which is 194.9% down from last year.
  • Per Harvard Bioscience's latest filing, its Other Operating Expenses stood at $5.5 million for Q3 2025, which was down 2019.85% from $5.9 million recorded in Q2 2025.
  • Over the past 5 years, Harvard Bioscience's Other Operating Expenses peaked at $54.3 million during Q1 2025, and registered a low of $5.5 million during Q3 2025.
  • Its 5-year average for Other Operating Expenses is $9.8 million, with a median of $7.4 million in 2022.
  • Data for Harvard Bioscience's Other Operating Expenses shows a peak YoY increase of 56138.0% (in 2025) and a maximum YoY decrease of 2019.85% (in 2025) over the last 5 years.
  • Over the past 5 years, Harvard Bioscience's Other Operating Expenses (Quarter) stood at $8.8 million in 2021, then dropped by 13.84% to $7.6 million in 2022, then increased by 0.69% to $7.6 million in 2023, then fell by 9.97% to $6.9 million in 2024, then dropped by 20.4% to $5.5 million in 2025.
  • Its Other Operating Expenses was $5.5 million in Q3 2025, compared to $5.9 million in Q2 2025 and $54.3 million in Q1 2025.